Why is Venmax Drugs falling/rising?

As of 17-Sep, Venmax Drugs & Pharmaceuticals Ltd is currently priced at 24.05, reflecting a decline of 0.72, or 2.91%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total drop of 12.1% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The delivery volume has also decreased significantly, with an 8.7k volume on 16 September, down 22.9% compared to the 5-day average. There are no positive or negative factors provided that could further explain the stock's recent movement.
Broader Market Context: In the short term, Venmax Drugs has underperformed compared to the benchmark Sensex, which has gained 1.56% over the past week while Venmax has only increased by 0.21%. Over the last month, the stock has seen a significant decline of 15.64%, contrasting sharply with the Sensex's rise of 2.60%. This disparity highlights the challenges Venmax is facing relative to the broader market, contributing to the downward pressure on its stock price.